Marvel Biosciences Announces Acceleration of Warrant Expiry Date

Core Points - Marvel Biosciences Corp. is accelerating the expiry date of warrants related to its non-brokered private placement unit offering, with the new expiry date set for November 5, 2025 [1][2] - As of October 3, 2025, 4,300,000 out of 5,000,000 warrants have been exercised, leaving 700,000 outstanding [2][3] - The company is developing MB-204, a novel drug aimed at treating neurological diseases, including autism, depression, and Alzheimer's Disease [3] Summary by Sections Company Announcement - Marvel Biosciences Corp. and its subsidiary Marvel Biotechnology Inc. are notifying about the acceleration of the expiry date of warrants from their private placement offering [1] - The offering consisted of 5,000,000 units priced at $0.10 each, with each unit including one common share and one warrant [1] Warrant Details - Each warrant allows the purchase of one common share at an exercise price of $0.15, expiring on July 19, 2026, unless the volume-weighted average trading price reaches $0.175 for five consecutive trading days [2] - The Triggering Event has occurred, leading to the new expiry date of November 5, 2025, for the remaining warrants [2] Company Vision and Product Development - The CEO, Rod Matheson, emphasized shareholder confidence with the exercise of 4,300,000 warrants, indicating strong belief in the company's vision and scientific foundation [3] - Marvel is focused on developing MB-204, a derivative of Istradefylline, to potentially treat various neurological disorders, expanding its therapeutic applications [3]